Which conditions are treated with cord blood transplants?

Cord blood bank brochures and websites often say that cord blood "can treat more than 80 diseases". The number is not invented. It also describes something narrower than it sounds, and the gap between the two matters for anyone deciding whether to donate or store a baby's cord blood.

This page explains where those lists come from, groups the conditions into families, and separates the established uses from the experimental ones.

Where the "80 diseases" lists come from

The lists are, in effect, catalogs of conditions for which doctors use a hematopoietic (blood-forming) stem cell transplant. Cord blood is one of three sources of those cells. The others are bone marrow and peripheral blood, where stem cells are coaxed out of the marrow with medication and collected from a vein. According to the National Cancer Institute, peripheral blood is the most commonly used source.

A transplant replaces a person's blood-forming system and, with it, the immune system. So it helps when the problem sits in the blood-forming cells themselves (leukemia, marrow failure, sickle cell disease), when a new immune system is needed, or when donor-derived cells can supply something the body lacks, such as a missing enzyme.

Three things inflate the count. Lists often split one disease into its subtypes, so five forms of myelodysplastic syndrome or seven types of mucopolysaccharidosis each count separately. Some entries are conditions where transplant is used only rarely, or where practice has moved on since the list was drafted. And a few entries are labeled experimental in small print.

None of this means transplant is a cure for the listed conditions, or a mild procedure. It involves high-dose chemotherapy or radiation, weeks of very low blood counts and real risks, including graft-versus-host disease. It is chosen when the disease is serious enough to justify that.

The condition families

The table groups the conditions most lists include. It describes why a transplant is used, not how often it works; outcomes vary widely by disease, age, stage and donor match.

Older lists also name cancers such as ovarian or small cell lung cancer. These reflect high-dose chemotherapy approaches tried in the 1990s and 2000s that are rarely used for those diseases now.

Two patterns stand out. First, several rows rely on the patient's own collected blood cells, not on cord blood at all. Second, the rows where cord blood genuinely matters are those needing a donor: leukemias, marrow failure and the inherited disorders of childhood.

Why a baby's own cord blood is rarely the right graft

For inherited diseases, the reason is simple. A child born with sickle cell disease, SCID or Hurler syndrome has the same genetic change in their cord blood as in the rest of their body. Transplanting those cells back would return the disease.

For leukemia, there are two reasons. Some childhood leukemias begin before birth: studies of newborn blood spots and cord blood have found leukemia-linked genetic changes in children who later developed the disease, so the stored cells may carry the first step toward it. And a key part of how donor transplants control leukemia is the donor's immune cells attacking leukemia cells, which a person's own cells cannot do.

For these reasons the American Academy of Pediatrics, in a 2017 policy statement, advised against private cord blood banking as "biological insurance" for a child's own future use, encouraged public donation and supported family-directed banking when a relative has a condition that a transplant could treat.

Most cord blood transplants use donated public units

Public banks collect donated cord blood, test it, record its tissue type (HLA) and list it on registries such as the US registry run by NMDP. Any matched patient can then use it. When this page was updated, the FDA's list of approved cellular and gene therapy products included nine licensed "HPC, Cord Blood" products from public banks, starting with Hemacord in 2011. The federal C.W. Bill Young Cell Transplantation Program, run by HRSA, supports the national inventory.

Cord blood's strengths are speed and flexibility. Units are already frozen and tested, and they tolerate a less perfect HLA match than adult donor cells, which helps patients whose ancestry is underrepresented among adult donors. Our piece on cord blood, genetic diversity and finding a match covers why. Its main weakness is the small number of cells in each unit, the problem behind the expansion methods on our page about growing more stem cells from one cord.

Adult donors remain the larger source of grafts. What giving marrow or peripheral blood involves for the donor is described in what blood stem cell donors go through.

There is one family situation where storing a newborn's cord blood for a specific person is widely supported: when an older brother or sister has a condition treatable by transplant. A full sibling has a 1 in 4 chance of being a complete HLA match, and several public and private banks run directed-donation programs for these families. Our page on cord blood banking compares public, private and hybrid models.

Established, changing and investigational uses

Established

Transplants with marrow, peripheral blood or cord blood are standard care in defined situations for the blood cancers, marrow failure states, inherited immune and metabolic diseases and red cell disorders in the table. FDA-licensed cord blood products carry an indication for rebuilding the blood and immune system in disorders affecting blood formation, not for brain or developmental conditions.

Changing

Some inherited conditions are moving from donor transplants toward gene therapy that uses the patient's own modified blood stem cells. The FDA approved gene therapies of this kind for an early form of cerebral adrenoleukodystrophy in 2022, for sickle cell disease in December 2023 and for metachromatic leukodystrophy in 2024. Half-matched family donor transplants have also grown, which has reduced how often cord blood is chosen for adults.

Investigational

• Autism. A randomized, placebo-controlled trial at Duke University in 180 children, published in The Journal of Pediatrics in 2020, found no improvement on its main measure of social communication after a single cord blood infusion. Cord blood for autism remains investigational.
• Cerebral palsy. Several small randomized studies have tested cord blood infusions, some reporting modest motor gains at higher doses. None has led to an approval; it remains investigational.
• Brain injury at birth (hypoxic-ischemic encephalopathy), type 1 diabetes and stroke have been studied in early trials. Our page on stem cells and type 1 diabetes covers that field.

Any of these offered outside a registered trial is not an established treatment. A trial can be checked on ClinicalTrials.gov using its NCT number, and our guide on how to read a ClinicalTrials.gov listing explains what to look for.

Four questions for any disease list

1. Does the list say which cell source each entry uses? Many entries are treated mostly with adult donor or the patient's own peripheral blood cells.
2. Is the transplant from a donor or from the patient's own cells? For inherited diseases and most leukemias, a child's own cord blood is not a suitable graft.
3. Is the use standard care or a trial? Entries marked experimental, or missing from transplant society guidelines, belong in the second group.
4. Who published the list? A list on a bank's sales page and a list from NMDP or a transplant center serve different purposes.

The most useful number on the subject is not 80. It is the 1 in 4 chance that a full sibling is a complete match, which is why directed donation for a family with a sick child is the one case where storing cord blood for a named person has clear medical value.